Human studies of radiolabeled anti-PD-1/PD-L1 antibodies, e.g.,[89Zr]Zr-atezolizumab, [89Zr]Zr-durvalumab and[89Zr]Zr-pembrolizumab, demonstrated that radiotracer tumoruptake was higher in patients with a response to immune checkpointtherapy.2,4,5 Additionally,tumor uptake correlated better with clinical response than immunohistochemistryor RNA-sequencing,2,4 and substantial intra- and intertumoraluptake heterogeneity was observed, reflecting the heterogeneity ofPD-L1 expression. The gene discussed is CD274; the disease is neoplasm.